<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557635</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0026</org_study_id>
    <nct_id>NCT00557635</nct_id>
  </id_info>
  <brief_title>Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow</brief_title>
  <official_title>Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Sometime osseous reconstruction needs allogeneic bone, in this study we use Ostéopure™ from
      Ostéobanque d'Auvergne, which is a osseous matrix. However Ostéopure™ integration lasts a
      long time. To optimize this integration we purpose to associate mesenchymal progenitors cells
      from autologous bone marrow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be treated for tibia or femur pseudo-arthrosis. At the beginning of
      chirurgical intervention, autologous bone marrow will be sampling and will be concentrated
      during this one.

      Meanwhile osseous matrix (Ostéopure™ ) will be incubated in autologous blood serum and
      finally implanted in the fracture site. And after (at the end of chirurgical intervention),
      concentrate autologous bone marrow will be injected in the same place.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    no recruited patients
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate osseous setting at 3-months follow-up and compare our results with past studies</measure>
    <time_frame>at 3-months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility and tolerance of this therapeutic strategy</measure>
    <time_frame>at 3-months follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tibia or Femur Pseudo-arthrosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chirurgical procedure</intervention_name>
    <description>Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  tibia or femur pseudo-arthrosis,

          -  patient who needs bone graft

        Exclusion Criteria:

          -  - contra indications for chirurgical intervention or bone graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Berger, Dr</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>September 22, 2009</last_update_submitted>
  <last_update_submitted_qc>September 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marc Berger</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>pseudo-arthrosis, osseous matrix, cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Pseudarthrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

